Previous 10 | Next 10 |
Stocks extended their recent gains on Friday, with the Dow rising by nearly 400 points. Even on a strong day for the broader averages, cryptocurrency stocks posted standout gains, as another big day for Bitcoin (BTC-USD) gave the sector a lift. Bolstered by the advance in their key underlying...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips 23andMe (NASDAQ: ME ) stock is running higher on Friday as investors pile on thanks to a recent interview on CNBC . Source: Connect world / Shutterstock.com The interview has EMJ Capital’s Eric Jackson...
Shares of genetic data miner 23andMe Holding (NASDAQ: ME) had surged 16% as of 12:15 p.m. EDT trading Friday after the stock received a positive mention on CNBC last night. As StreetInsider.com reports today, EMJ Capital founder Eric Jackson called 23andMe a "top pick" both ...
Gainers: Jasper Therapeutics (NASDAQ:JSPR) +22%, 23andMe (NASDAQ:ME) +21%, DBV Technologies (NASDAQ:DBVT) +10%, ABVC BioPharma (NASDAQ:ABVC) +10%, Sonoma Pharmaceuticals (NASDAQ:SNOA) +8% Losers: Grove (NASDAQ:GRVI) -12%, Myomo (NYSE:MYO) -11%...
4 Biotech Stocks To Watch In The Stock Market Today As the first week of the third-quarter earnings season comes to a close, biotech stocks continue to gain traction in the stock market now. Namely, between talk of booster shots and health care giants reporting new drug find...
Gainers: 23andMe Holding (NASDAQ:ME) +13%. Performant Financial Corporation (NASDAQ:PFMT) +4%. G1 Therapeutics (NASDAQ:GTHX) +3%. Kala Pharmaceuticals (NASDAQ:KALA) +3%. Avadel Pharmaceuticals (NASDAQ:AVDL) +3%. Losers: Duck Creek Technologies DCT -10%. Corsair Gaming CRS...
Rising inflationary pressure, a weak job market, and the Fed’s potential tapering could prolong stock market instability in the near term. However, the market is expected to generate some momentum later this month as the earnings season kicks off. As such, Wall Street analysts expect l...
23andMe is well known for their services around DNA testing, ancestry mapping, and genetic data. By collaborating with GlaxoSmithKline, the companies can better use 23andMe's 11.6 million genotyped customer database to develop beneficial drugs. Long-term investors should be focuse...
Consumer genetics testing company 23andMe Holding (NASDAQ: ME) recently went public via special purpose acquisition company merger, and longtime Fool.com contributor Matt Frankel, CFP, jumped at the opportunity to add shares to his portfolio. In this Fool Live video clip, reco...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Backed by billionaire Bill Ackman, Pershing Square Tontine (NYSE: PSTH ) may have been one of the hottest special purpose acquisition companies (SPACs) earlier this year. However, after what played out last month, tha...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...